地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:13212737804
邮箱:sales@amyjet.com

艾美捷科技有限公司代理Mimotopes公司多肽及多肽合成相关产品。Mimotopes公司位于澳大利亚,可以提供2000余种多肽,100余种药物及化妆品肽,1000余种各类氨基酸及多肽合成用试剂。
Mimotopes公司的主要产品类别:
(1)多肽(Peptides)
库存普通多肽(Catalogue Peptides)
化妆品肽(Cosmetic Peptides)
药物肽(Pharmaceutical Peptides)
肽库(Off-the-Shelf Library)
(2)氨基酸(Amino Acids)
Z Amino Acids
Unusual Amino Acids
N methyl Amino Acids
Fmoc Amino Acids
Common Amino Acids
Boc amino acids
AA attached_to_2-Chlorotrityl_Resin
AA attached_to_Wang_Resin
(3)多肽合成试剂(Peptides Synthesis Reagents)
Coupling Reagents
Amino Alcohols
General Reagents
Linkers
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Mimotopes"> Mimotopes
艾美捷科技代理Schircks Laboratories品牌。
瑞士Schircks Laboratories由B.Schircks博士于1980年创立,主要生产蝶啶及蝶啶类化合物(Pteridines)。至今,Schircks实验室合成了100多种蝶啶类化合物,主要用于科学研究和临床诊断应用。产品包括:
<| 11.180 | 6-(L-1,2,3-Trihydroxybutyl)-pterin [Rhamnopterin] |
| 11.182 | (6R,S)-5,6,7,8-Tetrahydro-L-rhamnopterin dihydrochloride |
| 11.203 | L-Biopterin [L-erythro-Biopterin] |
| 11.206 | 7,8-Dihydro-L-biopterin |
| 11.209 | (6R,S)-5,6,7,8-Tetrahydro-L-biopterin dihydrochloride |
| 11.212 | (6R)-5,6,7,8-Tetrahydro-L-biopterin dihydrochloride |
| 11.213 | (6R)-5,6,7,8-Tetrahydro-L-biopterin dihydrochloride |
| 11.215 | (6S)-5,6,7,8-Tetrahydro-L-biopterin sulfate |
| 11.216 | (6S)-5,6,7,8-Tetrahydro-L-biopterin sulfate |
| 11.217 | (6R)-5-Methyl-5,6,7,8-tetrahydro-L-biopterin dihydrochloride |
| 11.218 | D-Biopterin [D-erythro-Biopterin] |
| 11.220 | (6R,S)-5,6,7,8-Tetrahydro-D-biopterin dihydrochloride |
| 11.221 | D-threo-Biopterin [Dictyopterin] |
| 11.223 | (6R,S)-5,6,7,8-Tetrahydro-D-threo-biopterin dihydrochloride |
| 11.228 | Deoxysepiapterin |
| 11.229 | 6-((1R,S)-Hydroxypropyl)pterin [(1'R,S)-2'-Deoxybiopterin] |
| 11.231 | 7-Biopterin |
| 11.234 | 7-Tetrahydro-L-biopterin dihydrochloride |
| 11.260 | Oncopterin |
| 11.270 | 4-Hydroxy-6-(L-erythro-1,2-dihydroxy-propyl)-2-(methylthio)pteridine |
| 11.280 | 4-Amino-L-biopterin [2,4-Diamino-6-(L-erythro-1',2'-dihydroxypropyl)pteridine] |
| 11.282 | 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride |
| 11.283 | 4-Amino-(6R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride |
| 11.303 | D-Neopterin [D-erythro-Neopterin] |
| 11.306 | 7,8-Dihydro-D-neopterin |
| 11.307 | 7,8-Dihydro-D-neopterin-3’-triphosphate (Please refer to our reference 8) |
| 11.309 | (6R,S)-5,6,7,8-Tetrahydro-D-neopterin dihydrochloride |
| 11.314 | D-Neopterin-3’-monophosphate, lithium salt |
| 11.315 | 7,8-Dihydro-D-neopterin-3’-monophosphate, lithium salt |
| 11.320 | 3'-Hydroxy-D-sepiapterin |
| 11.330 | 7-Neopterin |
| 11.340 | L-Monapterin [L-threo-Neopterin] |
| 11.345 | 7,8-Dihydro-L-monapterin |
| 11.346 | (6R,S)-5,6,7,8-Tetrahydro-L-monapterin dihydrochloride |
| 11.349 | D-Monapterin [D-threo-Neopterin] |
| 11.403 | Pterin-6-carboxylic acid |
| 11.409 | Pterin-7-carboxylic acid |
| 11.415 | 6-Formylpterin [Pterin-6-aldehyde] |
| 11.416 | 6-Formyl-7,8-dihydropterin |
| 11.418 | Acetyl-6-formylpterin |
| 11.420 | 6-Hydroxymethylpterin |
| 11.421 | 6-Hydroxymethyl-7,8-dihydropterin hydrochloride |
| 11.422 | 6-Hydroxymethyl-7,8-dihydropterin-diphosphate (Please refer to our reference 8) |
| 11.423 | (6R,S)-6-Hydroxymethyl-5,6,7,8-tetrahydropterin dihydrochloride |
| 11.429 | 6-Hydroxymethylpterin-monophosphate |
| 11.438 | 6-Hydroxymethylpterin-diphosphate, lithium salt |
| 11.480 | 6-Methylpterin |
| 11.481 | 6-Methyl-7,8-dihydropterin hydrochloride |
| 11.483 | (6R,S)-6-Methyl-5,6,7,8-tetrahydropterin dihydrochloride |
| 11.503 | 6,7-Dimethylpterin |
| 11.506 | 6,7-Dimethyl-7,8-dihydropterin monohydrochloride |
| 11.509 | 6,7-Dimethyl-5,6,7,8-tetrahydropterin monohydrochloride |
| 11.703 | Leucopterin |
| 11.713 | Xanthopterin |
| 11.716 | Dihydroxanthopterin |
| 11.723 | Isoxanthopterin |
| 11.903 | Pterin |
| 11.906 | 7,8-Dihydropterin (Please refer to our reference 20) |
| 11.909 | 5,6,7,8-Tetrahydropterin dihydrochloride |
| 13.103 | Lumazine |
| 13.203 | 6-Hydroxylumazine |
| 13.206 | 6-Hydroxy-7,8-dihydrolumazine |
| 13.220 | 7-Hydroxylumazine |
| 16.113 | Pteroic acid |
| 16.123 | N10-(Trifluoroacetyl)pteroic acid |
| 16.140 | 10-Formylpteroic acid |
| 16.203 | Folic acid |
| 16.206 | 7,8-Dihydrofolic acid |
| 16.208 | (6S)-5,6,7,8-Tetrahydrofolic acid trihydrochloride |
| 16.209 | (6R,S)-5,6,7,8-Tetrahydrofolic acid trihydrochloride |
| 16.211 | 10-Methylfolic acid |
| 16.215 | 10-Formylfolic acid |
| 16.217 | 10-Formyl-5,6,7,8-tetrahydrofolic acid (Please refer to our reference 19) |
| 16.220 | (6R,S)-5-Formyl-5,6,7,8-tetrahydrofolic acid, calcium salt |
| 16.222 | (6R)-5-Formyl-5,6,7,8-tetrahydrofolic acid, calcium salt (unnatural calcium folinate) |
| 16.230 | (6R,S)-5,10-Methenyl-5,6,7,8-tetrahydrofolic acid chloride |
| 16.233 | (6R,S)-5-Methyl-5,6-dihydrofolic acid, ammonium salt |
| 16.235 | (6R,S)-5-Methyl-5,6,7,8-tetrahydrofolic acid, calcium salt |
| 16.236 | (6S)-5-Methyl-5,6,7,8-tetrahydrofolic acid, calcium salt |
| 16.243 | (6R,S)-5-Methyl-5,6,7,8-tetrahydropteroyltri-γ-L-glutamic acid trihydrochloride |
| 16.244 | (6R,S)-5-Methyl-5,6,7,8-tetrahydropteroyltetra-γ-L-glutamic acid trihydrochloride |
| 16.252 | Pteroyldi-γ-L-glutamic acid |
| 16.253 | Pteroyltri-γ-L-glutamic acid has been discontinued |
| 16.254 | Pteroyltetra-γ-L-glutamic acid |
| 16.255 | Pteroylpenta-γ-L-glutamic acid has been discontinued |
| 16.266 | Pteroylhexa-γ-L-glutamic acid, ammonium salt |
| 16.267 | Pteroylhepta-γ-L-glutamic acid, ammonium salt |
| 16.280 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroic acid |
| 16.282 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroyldi-γ-L-glutamic acid, lithium salt has been discontinued |
| 16.283 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroyltri-γ-L-glutamic acid, lithium salt has been discontinued |
| 16.284 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroyltetra-γ-L-glutamic acid, lithium salt |
| 16.285 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroylpenta-γ-L-glutamic acid, lithium salt |
| 16.286 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroylhexa-γ-L-glutamic acid, lithium salt |
| 16.330 | Aminopterin [4-Aminofolic acid] |
| 16.403 | 4-Amino-10-methylpteroic acid (APA, DAMPA) |
| 16.411 | Methotrexate [4-Amino-10-methylpteroyl-γ-L-glutamic acid] |
| 16.412 | 4-Amino-10-methylpteroyldi-γ-L-glutamic acid, ammonium salt [Methotrexate diglutamate] |
| 16.413 | 4-Amino-10-methylpteroyltri-γ-L-glutamic acid, ammonium salt [Methotrexate triglutamate] |
| 16.414 | 4-Amino-10-methylpteroyltetra-γ-L-glutamic acid, ammonium salt [Methotrexate tetraglutamate] |
| 16.415 | 4-Amino-10-methylpteroylpenta-γ-L-glutamic acid, ammonium salt [Methotrexate pentaglutamate] |
| 16.416 | 4-Amino-10-methylpteroylhexa-γ-L-glutamic acid, ammonium salt [Methotrexate hexaglutamate] |
| 16.417 | 4-Amino-10-methylpteroylhepta-γ-L-glutamic acid, ammonium salt [Methotrexate heptaglutamate] |
| 16.500 | 7-Hydroxymethotrexate |
| 16.701 | p-Aminobenzoyl-L-glutamic acid |
| 16.702 | p-Aminobenzoyldi-γ-L-glutamic acid, ammonium salt |
| 16.703 | p-Aminobenzoyltri-γ-L-glutamic acid, ammonium salt |
| 16.704 | p-Aminobenzoyltetra-γ-L-glutamic acid, ammonium salt |
| 16.705 | p-Aminobenzoylpenta-γ-L-glutamic acid, ammonium salt |
| 16.706 | p-Aminobenzoylhexa-γ-L-glutamic acid, ammonium salt |
| 16.707 | p-Aminobenzoylhepta-γ-L-glutamic acid, ammonium salt has been discontinued |
| 16.901 | Z-Glu-OtBu |
| 16.902 | Z-Glu2-OtBu3 |
| 16.903 | Z-Glu3-OtBu4 |
| 16.904 | Z-Glu4-OtBu5 |
| 16.905 | Z-Glu5-OtBu6 |
| 16.906 | Z-Glu6-OtBu7 |
| 91.303 | D-(5-15N)-Neopterin |
| 96.203 | (5-15N)-Folic acid |

艾美捷科技代理EastCoast Bio品牌诊断原料。
EastCoast Bio公司,主要生产诊断试剂行业抗原和抗体,在药物滥用、传染病、动物诊断领域独具特色。EastCoast Bio公司成立于1995年,总部位于美国。该公司致力于提供高质量的抗原、抗体和用于诊断试剂生产的免疫分析试剂。其产品在胶体金和ELISA等免疫测定法中得到了广泛应用,为全球大小型制造商开发自己的免疫测定法提供了有力支持。EastCoast Bio公司提供多种心肌类、肿瘤类、激素类、传染病类等抗原抗体产品。这些产品具有高灵敏度、高特异性和高稳定性等特点,能够满足不同领域的检测需求。例如,心肌类抗原抗体可用于心脏疾病的诊断;肿瘤类抗原抗体可用于肿瘤的早期筛查和疗效监测;传染病类抗原抗体则可用于传染病的诊断和防控。除了抗原和抗体产品外,EastCoast Bio公司还提供一系列用于免疫分析的试剂,如海洋阻断剂、药物滥用抗原抗体(DOA)、血浆蛋白等。这些试剂在免疫测定法中发挥着重要作用,有助于提高检测的准确性和可靠性。EastCoast Bio公司的产品线还包括mRNA疫苗相关产品、化合物、修饰酶以及其他PCR相关试剂等。这些产品为生命科学研究和临床诊断提供了更多的选择和可能性。
" data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理EastCoast Bio品牌诊断原料"> 艾美捷科技代理EastCoast Bio品牌诊断原料

艾美捷科技代理LifeSensors品牌。
LifeSensors成立于1996年,位于美国宾夕法尼亚州费城,是一家为药物发现与研究提供方法和可行性技术方法的生物技术公司。公司致力于为泛素和泛素蛋白酶体通路研究领域提供高品质
的抗体、酶、蛋白质等试剂和试剂盒,产品,是泛素研究者的好选择。
其原核和真核蛋白表达系统SUMOpro和SUMOstar已被世界范围内的学术、政府研究机构和制药、生物技术公司广泛应用。通过提供创新的研究工具,LifeSensors已成为泛素和泛素样蛋
白途径的优质供应商。
LifeSensors公司目前主要的产品有400多种,其产品主要覆盖泛素和泛素蛋白酶体通路等科学应用领域,并且产品线在不断的扩大中。公司开创了两大独家技术平台:用于细胞信号和药物
发现的泛素蛋白酶体系统(UPS),以及增强目的蛋白在大肠杆菌、酵母、昆虫和哺乳动物细胞中表达与纯化的SUMO融合表达系统。泛素蛋白酶体系统正在成为继激酶之后,药物发现的下
一个机遇,必将成为未来许多新型药物的创新来源。作为泛素蛋白领域的先驱公司,药物的发现、分析化合物以及去泛素酶和泛素化酶的高通量筛选正是LifeSensors创新技术的真正亮点。
此外,LifeSensors还为泛素的蛋白质组学提供众多定制技术服务,并且已经开发了各种各样的测定细胞中的生理底物或生物标志物的方法。
< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理LifeSensors品牌"> 艾美捷科技代理LifeSensors品牌
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理Protide Pharmaceuticals品牌全系列产品
Protide Pharmaceuticals, Inc.是一家专注于生物制药生产上游工艺的创新型公司。Protide Pharmaceuticals公司的核心产品为血清替代物,其核心价值在于提供高性能、化学成分明确、无动物来源的血清替代物和定制化培养基解决方案,帮助客户大幅减少生物制品生产过程中对胎牛血清或其他动物血清的依赖。,从而提高生物制品生产的效率、一致性、安全性和合规性。
除了血清替代物,Protide Pharmaceuticals公司也提供完整的、优化的无血清培养基配方,专门设计用于支持各种哺乳动物细胞系(如CHO, HEK293, Vero, MRC-5等)在生物反应器中进行高密度培养和高产率生产目标生物分子(如抗体、病毒载体、重组蛋白)。其产品应用于再生医学、肿瘤生物学、细胞生物能量学、肿瘤免疫学、转化医学、表观遗传学,胰岛细胞移植等领域。

▎Protide Pharmaceuticals产品线
● 血清替代品/生物制品生产培养基
Protide Pharmaceuticals的血清替代品通过提供优质、生物一致且功能性的环境,显著改善细胞的生理状态。所有血清替代品均配制成 50 倍浓缩液,这大大降低了成本,并改善了储存和供应链活动。Protide血清替代品不含:酚红、生长因子、类固醇激素、糖皮质激素、细胞粘附分子、生长因子、类固醇激素等物质,可以在其缺失或存在的情况下进行有效研究。细胞分泌的蛋白质可以在不受污染性血清成分干扰的情况下实现高度纯化。
| 品名 | 货号-规格 | 产品描述 |
| TCH™ | 3001-40ml;3002-100ml;3005-100ml | 本血清替代品主要用于人类细胞培养及细胞分泌蛋白的生产。TCH™ 在培养其他哺乳动物细胞时同样有效,且不含动物蛋白。其成分仅包含经热处理的人源蛋白(即人血清白蛋白、人转铁蛋白、重组人胰岛素)。 |
| VaxMax™ | 6004-100ml;6005-500ml;6006-1L | 100倍浓缩液是一种高性价比产品,可显著降低总体血清需求量。在MDBK、MDCK、Vero、CRFK及猪睾丸细胞培养中,使用VaxMax™已展现出显著的产量提升。兽用疫苗生产商已采用VaxMax™来增强生产,同时降低总体成本。VaxMax™通常与0.5%至1% 的血清配合使用。 |
| HemaPro™ | 3300-40ml;3303-100ml | 本产品为无血清添加剂,专为人祖细胞培养而设计。可有效用于癌症干细胞、诱导多能干细胞和间充质干细胞 的研究。不含:促红细胞生成素;重组生长因子。 |
| TM-235™ | 2001-40ml;2002-100ml;2005-500ml | 本血清替代品具有与TCM™类似的特性,但额外添加了适用于需要更高血清浓度(通常超过10%)的细胞类型的成分。TM-235™是一种成分明确且多用途的替代品。 |
| TCM™ | 1001-40ml;1002-100ml;1005-500ml | 本产品是一种通用型血清替代品,适用于多种物种来源的广泛细胞类型。TCM™是一种成分明确且多用途的血清替代品,可有效用于研究生长因子的影响以及蛋白质的生产。 |
● 低温保护剂
| 品名 | 货号-规格 | 产品描述 |
| Stemsol™ USP (DMSO) | PP1250-5ml;PP1300-10ml;PP1350-50ml;PP1400-100ml | 本产品为干细胞冻存溶液,适用于来源于脐带血、外周血、骨髓及其他生物组织和细胞的干细胞。 |
| pZerve™ | 5700-60ml;5720-20ml | pZerve™ 是一款独特的冻存溶液,不含 DMSO、胎牛血清或动物蛋白。本品为即用型,无需任何稀释或进一步处理。适用细胞类型包括:肥大细胞、树突细胞、间充质细胞、人转移性前列腺腺癌细胞、人结肠腺癌细胞,人转化胚肾细胞。 |
| Cellvation™ | 5001-60ml | Cellvation™ 是一款独特的冻存溶液,不含 DMSO 或胎牛血清。本品使用便捷,并能提供最佳的细胞复苏效果。在冷冻程序启动前,细胞可置于 Cellvation™ 中较长时间。本品为即用型,适用于无血清培养基或含血清培养基培养的细胞。 |
| MiCord™ 55% DMSO USP 5% Dextran USP | 1505-5ml;1500-7ml;;1700-10ml;1550-50ml;1600-100ml | 本产品为干细胞冻存溶液,适用于来源于脐带血、外周血、骨髓及其他生物组织和细胞的干细胞。 |
| 2-8CELLsius™ + DMSO,5% DMSO | PP338DM5-10ml;PP338DM5-100ml;PP338DM5-100B | 当与DMSO配合使用时,2-8CELLsius™可用作冻存液。2-8CELLsius™ + DMSO冻存液是一种细胞保护性、无蛋白溶液,含有生物稳定剂,可支持冻融后细胞的高存活率。其通过针对超低温下细胞生理学的创新方法,实现最佳的细胞复苏效果。不含:任何生长因子,激素以及抗生素。 |
| 2-8CELLsius™ + DMSO,10% DMSO | PP338DM10-10ml;PP338DM10-100ml;PP338DM10-100B;PP338DM10-1000B | |
| 2-8CELLsius™ + DMSO,20% DMSO | PP338DM20-100B;PP338DM20-1000B |
● 细胞处理
| 品名 | 货号-规格 | 产品描述 |
| 2-8CELLsius™ | PP338-100ml;PP338-500ml;PP338-1000;PP338-1000B | 即用型、平衡、细胞保护性、无蛋白溶液,含生物稳定剂,适用于:短期储存、再生医学、干细胞处理以及生物材料运输。 |
| Dextran 40 in 0.9% NaCl | PP1850-50ml;PP1840-1000ml;PP1880-250ml;PP1900-500ml | - |
| Dulbecco’s Phosphate Buffered Saline (10X) PBS | PBS210-500ml;PBS211-1000ml | 无钙镁储存条件:15-30°C;包装于PETG瓶;稳定性:至少6个月;无菌过滤 |
| Dulbecco’s Phosphate Buffered Saline (1X) PBS | PBS200-500ml;PBS201-1000ml | 无钙镁储存条件:15-30°C;包装于PETG瓶;稳定性:至少6个月;无菌过滤 |
| Hank’s Balanced Salt Solution (1X) HBSS | HS240-500ml;HS241-1000ml | 无钙镁配方:储存温度 4-8°C;无酚红配方;稳定性:至少6个月;含0.35克/升 碳酸氢钠;含1000毫克/升 D-葡萄糖;包装于 PETG 瓶,无菌过滤。cGMP 规范生产。 |
● CIT 胰岛细胞溶液
| 品名 | 货号-规格 |
| Cold Storage/Purification Stock Solution | 111098-1L |
| Phase I Solution | 060899-1L |

艾美捷科技代理NeXtal Biotechnologies品牌。
NeXtal Biotechnologies 是一家专注于为结构生物学和药物发现领域提供高质量试剂、耗材和工具的公司。公司致力于支持科学家在蛋白质晶体学、小分子晶体学和药物筛选等领域的研究,提供从蛋白质纯化到晶体生长的全流程解决方案。NeXtal Biotechnologies核心业务领域:
(1)蛋白质纯化工具:NeXtal Biotechnologies 提供用于蛋白质纯化的工具和试剂,如亲和层析柱、蛋白质浓缩器和透析设备。
(2)晶体生长试剂:公司提供多种用于蛋白质和小分子晶体生长的试剂,包括结晶筛选试剂盒、缓冲液、沉淀剂和添加剂。
(3)结晶筛选试剂盒:NeXtal Biotechnologies 提供多种结晶筛选试剂盒,如 JCSG+、Morpheus 和 PACT,适用于不同类型的晶体生长实验。
(4)晶体学耗材:提供用于晶体学研究的耗材,如结晶板、密封膜、样品支架和低温冷冻工具。这些耗材与主流X射线衍射仪兼容,支持从晶体生长到数据收集的全流程。
(5)自动化晶体成像系统:NeXtal Biotechnologies 提供自动化晶体成像系统(如 Rock Imager),用于实时监测晶体生长过程,帮助科学家优化晶体生长条件。
(6)药物筛选工具:公司提供用于药物筛选的工具和试剂,如蛋白质-配体结合分析试剂盒和高通量筛选板。
< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理NeXtal Biotechnologies品牌"> 艾美捷科技代理NeXtal Biotechnologies品牌
<艾美捷科技代理Accuplexdiagnostics品牌全系列产品
Accuplex Diagnostics成立于2011年,是一家专注于开发新型诊断测试的企业,其目标市场涵盖兽医、人类和研究应用领域。在产品开发和国际营销积累了超过50年的丰富经验,致力于开发新的诊断测试,旨在简化已确定需求领域的生物标志物检测。Accuplex Diagnostics在爱尔兰梅努斯大学设有校内基地,为马匹和一般兽医实践提供测试套件,体现了其产学研结合的发展模式。
Accuplex Diagnostics的产品——OmniChek-SAA™通过检测血清淀粉样蛋白A(SAA)这一炎症生物标志物能快速检测多物种炎症情况,并具有以下特征:
● 广泛适用性:可检测多种物种的炎症情况,包括狗、兔子、猫、海豹、狒狒、猴子以及生产动物等。在兽医临床、动物研究以及生产动物健康管理等多个领域有重要的应用价值。
● 快速简便:运行快速且操作简单,只需使用一滴全血即可方便地使用,大大节省了检测时间和操作成本。
● 多场景应用:除了动物检测外,还可应用于其他重要领域,为兽医、动物主人和其他相关利益者提供了一个有用的新工具,有助于及时发现和处理动物的健康问题。

▍Accuplexdiagnostics产品列表
| 品名 | 产品描述 |
| EquiChek™-SAA | EquiChek™-SAA is a simple stall-side test that provides veterinarians, trainers or breeders with the opportunity to test for any inflammatory condition, including infections, where it matters, beside the horse. Blood can be analyzed without the need to send samples to a lab. In just two simple steps, you can tell if the horse has an active inflammatory condition. |
| OmniChek™-SAA | OmniChek™-SAA is a simple animal-side test that provides veterinarians or animal carers and owners with the opportunity to test for inflammatory conditions, including infections, where and when it matters, beside the animal in the surgery, field, or home. All that is needed is a tiny drop of blood and analysis is performed without the need of a laboratory. In just two simple steps, you can tell if the animal has an active inflammatory condition such as acute infection. |
| SideroTec™-Total Assay Kit | The SideroTec-Total kits contains all the reagents required for Siderophore detection with sufficient materials to run up to 110 tests. It can be used for both qualitative as well as quantitative assay and can be used either manually or automated for high throughput screening. With minimal set up and rapid assay time, the SideroTec-Total assay kit is a convenient and cost-effective method for siderophore detection. |
| SideroTec-HiSens™ Assay | The SideroTec-HiSens™ assay uses a single addition ready-to-use fluorescent label for detection of siderophores and other iron chelation molecules in aqueous, organic, or biological samples. |
| SideroTec-AsP™ | The SideroTec-AsP™ is an ELISA* that enables detection of the fungus Aspergillus fumigatus responsible for Invasive Aspergillosis (IA), an infection which can prove fatal to patients with other underlying conditions including those with cancer, organ transplant patients or anyone who may be immunocompromised. It is now recognised that many patients with COPD also have invasive pulmonary aspergillosis but remain undetected.During the Covid pandemic, IA caused up to 30% of all deaths in ICU. |
<艾美捷科技有限公司授权代理Katchem公司全系列产品。
产品详情请见艾美捷科技丁香通商铺或直接咨询客服人员。
https://vicbio.biomart.cn/supply/c_307368.htm

Katchem公司,位于捷克共和国Prague,是一家主要生产硼化学产品的公司,其产品主要包括:硼酸盐和碳硼酸盐簇、十硼烷(14)簇、碳硼烷、COSANes、金属硼氢化物、硼砂及其衍生物、硼烷-路易斯碱配合物、硼酸和酯、BNCT用化合物、非硼化合物、二氨基甲酸盐和催化系统等。
【产品应用场景1】
中子治疗,硼中子俘获治疗(Boron Neutron Capture Therapy,简称BNCT)。
BNCT的原理是利用发生在肿瘤细胞内的核反应摧毁癌细胞,由于同时需要中子源和B,因此,是一种二元化治疗肿瘤的新方法。BNCT的基本过程分为两部分:首先在肿瘤细胞内聚积足够量的稳定性核素B,即将一种含B的化合物引入患者体内,这种化合物与肿瘤细胞有很强的亲和力,进入体内后,迅速聚集于肿瘤细胞内,而在其它正常组织中分布很少;然后再用中子束照射肿瘤部位,使中子与肿瘤细胞内聚集的B发生B(n,α)Li核反应,B俘获中子后,形成同位素B,B迅速分裂为重粒子Li和α,肿瘤细胞被α射线和Li照射而死亡。适用于硼中子捕获治疗的含硼化合物应具备四个重要特性:对人体毒性低、对正常细胞的亲和性低、对癌细胞的亲和性高(最好可达正常细胞的3倍以上,且每克癌细胞分布的硼达到20微克以上)、能被人体迅速从正常细胞和血液移除。目前仅有两种含硼化合物应用在临床试验:Sodium Borocaptate (BSH)以及Boronophenylalanine(BPA)。
【产品应用场景2】
电池研发。

【热销产品】









【产品列表】
| 产品编码 | 产品名称 | CAS号 | 规格(g) |
| 410 | Sodium triborate dioxane | CAS [33220-35-8] | 1、5、10、25、50 |
| 458 | Cesium triborate | CAS [12007-45-3] | 1、5、10 |
| 564 | LIthium triborate dioxane | CAS [212697-88-6] | 1、5、10 |
| 315 | Triethylammonium decahydrodecaborate | CAS [12075-73-9] | 5、10、25、50、100 |
| 333 | Tetramethylammonium decahydrodecaborate | CAS [12073-87-9] | 5、10、25、50、100 |
| 493 | Sodium decahydrodecaborate | CAS [12294-20-1] | 5、10、25、50、100 |
| 459 | Ammonium decahydrodecaborate | CAS [12008-61-6] | 5、10、25、50、100 |
| 229 | Potassium decahydrodecaborate | CAS [12447-89-1] | 5、10、25、50、100 |
| 246 | Cesium decahydrodecaborate | CAS [12008-58-1] | 10、25、50、100 |
| 675 | Lithium decahydrodecaborate, trihydrate | CAS [64719-89-7 anhyd] | 5、10、25 |
| 812 | Calcium decahydrodecaborate, trihydrate | CAS [64719-84-2 anhyd] | 5、10、25 |
| 804 | Cesium decachlorodecaborate | CAS [12360-16-6] | 5、10、25、50 |
| 805 | Cesium decabromodecaborate | CAS [12356-10-4] | 5、10、25、50 |
| 803 | Cesium decaiododecaborate | CAS [88423-95-4] | 5、10、25、50 |
| 324 | Cesium tetradecahydroundecaborate | CAS [12008-72-9] | 5、10、25、50、100 |
| 453 | Triethylammonium tetradecahydroundecaborate | CAS [12106-44-4] | 5、10、25、50、100 |
| 614 | Potassium tetradecahydroundecaborate | CAS [52261-21-9] | 5、10、25、50、100 |
| 615 | Sodium tetradecahydroundecaborate | CAS [52261-23-1] | 5、10、25、50、100 |
| 372 | Trimethylammonium tetradecahydroundecaborate | CAS [12076-74-3] | 5、10、25、50、100 |
| 684 | Lithium tetradecahydroundecaborate, trihydrate | CAS [52261-22-0 anhyd.] | 1、5、10 |
| 815 | Calcium tetradecahydroundecaborate, dihydrate | 1、5、10 | |
| 290 | Triethylammonium dodecahydrododecaborate | CAS [12551-42-7] | 5、10、25、50、100、250、1000 |
| 316 | Cesium dodecahydrododecaborate | CAS [12008-75-2] | 5、10、25、50、100、250、1000 |
| 228 | Potassium dodecahydrododecaborate | CAS [12008-77-4] | 5、10、25、50、100、250、1000 |
| 257 | Sodium dodecahydrododecaborate | CAS [12008-78-5] | 5、10、25、50、100、250、1000 |
| 328 | Sodium dodecahydrododecaborate anhydrous, <0.1% water | CAS [12008-78-5] | 5、10、25、50、100、250 |
| 569 | Lithium dodecahydrododecaborate, tetrahydrate | CAS [1166383-94-3] | 5、10、25、50、100、250、1000 |
| 445 | Magnesium dodecahydrododecaborate, tetrahydrate | CAS [53572-04-6 anhyd.] | 5、10、25 |
| 446 | Cobalt dodecahydrododecaborate, dihydrate | ||
| 597 | Calcium dodecahydrododecaborate monohydrate | CAS [90157-87-2 anhyd.] | 5、10、25 |
| 492 | Rubidium dodecahydrododecaborate | CAS [12598-46-8] | 5、10、25 |
| 243 | Sodium dodecachlorododecaborate | CAS [111637-82-2] | 5、10、25、100 |
| 244 | Sodium dodecabromododecaborate | CAS [1253735-09-9] | 5、10、25、100 |
| 550 | Sodium dodecaiodododecaborate | CAS [149211-37-0] | 5、10、25、100 |
| 544 | Sodium hydroxydodecaborate | CAS [56189-13-0] | 1、5、10 |
| 347 | Cesium dodecahydroxydodecaborate | CAS [12589-26-3] | 1、5、10、50 |
| 211 | Sodium mercaptododecaborate, N-BSH | CAS [144885-51-8] | 1、5、10、25、50 |
| 266 | Cesium mercaptododecaborate, N-BSH | CAS [12448-23-6] | 1、5、10、25、50 |
| 587 | Tetramethylammonium mercaptododecaborate, N-BSH | CAS [135274-62-3] | 1、5、10、25、50 |
| 489 | syn -Octadecaborane(22) | CAS No. [21107-45-9] | 1、5、10 |
| 488 | anti -Octadecaborane(22) | CAS No. [21107-56-2] | 1、5、10 |
| 359 | Mixture of syn - and anti -octadecaboranes(22) | 1、5、10、20 | |
| 414 | Triethylammonium decahydrodecaborate 10B | ||
| 556 | Sodium decahydrodecaborate 10B, GB-10 | CAS [12373-10-3] | 1、5、10、25 |
| 258 | Triethylammonium dodecahydrododecaborate 10B | 1、10、25、50 | |
| 226 | Sodium dodecahydrododecaborate 10B | CAS [109851-98-1] | 1、10、25、50 |
| 588 | Cesium dodecahydrododecaborate 10B | CAS [109788-95-6] | 1、10、25、50 |
| 500 | Lithium dodecahydrododecaborate 10B, tetrahydrate | CAS [51745-90-5 anhyd.] | 1、10、25、50 |
| 210 | Sodium mercaptododecaborate 10B, BSH | CAS [12448-24-7] | 1、5、10、50 |
| 603 | Tetramethylammonium mercaptododecaborate 10B | CAS [130207-66-8] | 1、5、10、50 |
| 401 | Cesium mercaptododecaborate 10B | CAS [109742-44-1] | 1、5、10、50 |
| 486 | Triethylammonium dodecahydrododecaborate 11B | 1、10、25、50 | |
| 491 | Sodium dodecahydrododecaborate 11B | 1、5、10 | |
| 466 | Cesium dodecahydrododecaborate 11B | CAS [1347742-49-7] | 1、5、10 |
| 485 | Rubidium dodecahydrododecaborate 11B | CAS [1347742-48-6] | 1、2、5、10 |
| 450 | Sodium mercaptododecaborate 11B | CAS [459142-76-8] | 1、5、10 |
| 457 | Cesium carbaundecaborate | CAS [51391-30-1] | 1、5、10、25、50、100、250 |
| 456 | 7-Amino-7-carbaundecaborate | CAS [12373-10-3] | 1、5、10、25、50、100 |
| 264 | 7-Trimethylamino-7-carbaundecaborate | CAS [31117-16-5] | 1、5、10、25、50、100、250 |
| 676 | Sodium carbaundecaborate | CAS [68084-95-7] | 1、5、10 |
| 677 | Lithium carbaundecaborate, hemihydrate | CAS [2169943-32-0] | 1、5、10 |
| 251 | 1-Amino-1-carbadodecaborate | CAS [749831-19-4] | 1、5 |
| 252 | 1-Trimethylamine-1-carbadodecaborane | CAS [92468-34-3] | 1、5 |
| 212 | Trimethylammonium carbadodecaborate | CAS No.[108608-25-9] | 1、5、10、20、50 |
| 213 | Cesium carbadodecaborate | CAS No.[12539-26-3] | 1、5、10、20、50 |
| 421 | Triethylammonium carbadodecaborate | CAS No.[223548-06-9] | 1、5、10、20、50 |
| 242 | Potassium carbadodecaborate | CAS No.[92468-39-8] | 1、5、10、20、50 |
| 647 | Sodium carbadodecaborate | CAS No.[92468-38-7] | 1、5、10、20、50 |
| 648 | Lithium carbadodecaborate hemihydrate | CAS No.[92468-37-6 anhyd.] | 1、5、10、20、50 |
| 813 | Calcium carbadodecaborate trihydrate | CAS No.[2077150-90-2 anhyd.] | 1、5、10、20、50 |
| 523 | Cesium 1-methyl-1-carbadodecaborate new | CAS No.[176099-40-4] | 1、5、10 |
| 349 | Trimethylammonium 1-propyl-1-carbadodecaborate new | 1、5、10 | |
| 351 | Trimethylammonium 1-mercapto-1-carbadodecaborate new | 1、5、10 | |
| 365 | Trimethylammonium 1-hydroxy-1-carbadodecaborate new | CAS No.[2077207-91-9] | 1、5、10 |
| 366 | Trimethylammonium 1-carboxy-1-carbadodecaborate new | CAS No.[1252604-78-6] | 1、5、10 |
| 378 | Cesium closo -1-carbadecaborate | CAS No.[12539-20-7] | 1、5、10 |
| 649 | Sodium closo -1-carbadecaborate | CAS No.[94322-26-6] | 1、5、10 |
| 650 | Lithium closo -1-carbadecaborate, hydrate | CAS No.[94322-25-5 anhyd.] | 1、5、10 |
| 814 | Calcium closo -1-carbadecaborate, dihydrate | 1、5、10 | |
| 412 | Trimethylammonium 7,8-dicarbaundecaborate | CAS No.[12543-22-5] | 1、5、10、25、50、100 |
| 613 | Cesium 7,8-dicarbaundecaborate | CAS No.[63748-65-2] | 1、5、10、25、50、100 |
| 673 | Sodium 7,8-dicarbaundecaborate | CAS No.[12602-34-5] | 1、5、10、25、50、100 |
| 682 | Lithium 7,8-dicarbaundecaborate dihydrate | CAS No.[1629094-87-6 anhyd.] | 1、5、10、25、50、100 |
| 214 | Trimethylammonium 7-methyl-7,8-dicarbaundecaborate | 1、5、10、25、50 | |
| 495 | Trimethylammonium 7,9-dicarbaundecaborate | CAS No.[54531-56-5] | 1、5、10、25、50、100 |
| 384 | Cesium 7,9-dicarbaundecaborate | CAS No.[12305-33-8] | 1、5、10、25、50、100 |
| 674 | Sodium 7,9-dicarbaundecaborate | 1、5、10、25、50、100 | |
| 683 | Lithium 7,9-dicarbaundecaborate trihydrate | CAS No.[1629094-86-5 anhyd.] | 1、5、10、25、50、100 |
| 208 | Decaborane(14) | CAS [17702-41-9] | 1、5、10、25、50、100、250 |
| 419 | Bis(acetonitrile)-decabora | CAS [28377-97-1] | 5、20、100、250 |
| 238 | Bis(dimethylsulfide)-decaborane | CAS [28377-92-6] | 5、20、100、250 |
| 204 | Decaborane(14) 10B(Isotopic enrichment: 10B >99.5%) | CAS [488806-75-3] | 1、5、10、25 |
| 301 | Decaborane(14) 11B(Isotopic enrichment: 11B >99.8%) | CAS [94601-45-3] | 1、5、10、25 |
| 199 | o -Carborane | CAS No. [16872-09-6] | 1、5、10、25、50、100、250、500 |
| 209 | 1-Methyl-o -carborane | CAS No. [16872-10-9] | 5、10、25、50、100 |
| 233 | 1-Bromomethyl-o -carborane | CAS No. [19496-84-5] | 5、10、25、50、100 |
| 269 | 1,2-Dimethyl-o -carborane | CAS No. [17032-21-2] | 1、5、10 |
| 332 | 1-n-Propyl-o -carborane | CAS No. [23940-16-1] | 1、5、10 |
| 463 | 1-Hexyl-o -carborane | CAS No. [20740-05-0] | 1、5、10、25、50、100 |
| 464 | 1,2-Dihexyl-o -carborane | CAS No. [280762-92-7] | 1、5、10、25、50 |
| 203 | 1-Phenyl-o -carborane | CAS No. [16390-61-7] | 1、5、10、25、50、100 |
| 465 | 1,2-Didodecyl-o -carboran | CAS No. [943026-62-8] | 1、5、10、25、50 |
| 609 | 1-Methyl-2-propargyl-o -carborane | CAS No. [23868-57-7] | 1、2、5 |
| 318 | 1-Hydroxymetyl-o -carborane | CAS No. [19610-34-5] | 1、5、10 |
| 448 | 1,2-Bis(hydroxymethyl)-o -carborane | CAS No. [19610-37-8] | 1、5、10 |
| 297 | o -Carborane-1-carboxylic acid | CAS No. [18178-04-6] | 1、5、10 |
| 253 | o -Carborane-1,2-dicarboxylic acid | CAS No. [23835-80-5] | 1、5、10 |
| 480 | 1-Trimethylsilyl-o -carborane | CAS No. [18971-67-0] | 1、5、10、25 |
| 516 | 1-Hydroxy-o -carborane | CAS No. [23987-99-7] | 1、2、5、10 |
| 502 | 1,2-Dihydroxy-o -carboran | CAS No. [868382-62-1] | 1、2、5、10 |
| 293 | 1-Mercapto-o -carborane | CAS No. [17526-07-7] | 1、5、10、25 |
| 232 | 1,2-Dimercapto-o -carbora | CAS No. [23810-63-1] | 1、5、10、25 |
| 345 | 9-Iodo-o -carborane | CAS No. [17830-03-4] | 5、10、20 |
| 346 | 9,12-Diiodo-o -carborane | CAS No. [17702-35-1] | 5、10、20 |
| 240 | 9-Mercapto-o -carborane | CAS No. [64493-43-2] | 1、5、10 |
| 433 | 9,12-Dimercapto-o -carborane | CAS No. [75572-47-3] | 1、2、5 |
| 440 | 8,9,12-Trimercapto-o -carborane | CAS No. [1423066-18-5] | 1、2、5 |
| 200 | m -Carborane | CAS No. [16986-24-6] | 1、5、10、25、50、100、250 |
| 518 | 1-Methyl-m -carborane | CAS No. [17378-55-1] | 1、5、10、25 |
| 317 | 1-Allyl-7-methyl-m -carbor | CAS No. [20670-09-1] | 1、5、10、25 |
| 319 | 1,7-Diallyl-m -carborane | CAS No. [1232168-57-8] | 1、5、10、25 |
| 320 | 1,7-Bis(hydroxymethyl)-m -carborane | CAS No. [23924-78-9] | 1、5、10、50 |
| 298 | m -Carborane-1-carboxylic acid | CAS No. [18581-81-2] | 1、5、10 |
| 261 | 1,7-Bis(chlordimethylsilyl)-m -carborane | CAS No. [16996-48-8] | 1、5、10、50、100、250 |
| 259 | 1,7-Bis(methoxydimethylsilyl)-m -carborane | CAS No. [17631-41-3] | 1、5、10、50、100、250 |
| 321 | 1,7-Bis(hydroxydimethylsilyl)-m -carborane | CAS No. [22742-19-4] | 1、5、10、50、100、250 |
| 481 | 1-Vinyldimethylsilyl-m -carborane | 1、5、10、25 | |
| 501 | 1,7-Bis(vinyltetramethyldisiloxy)-m -carborane | CAS No. [210707-88-3] | 1、5、10、25、50 |
| 527 | 1-Hydroxy-m -carborane | CAS No. [23988-02-5] | 1、5、10 |
| 532 | 1,7-Dihydroxy-m -carbora | CAS No. [55629-26-0] | 1、5、10 |
| 496 | 1-Mercapto-m -carborane | CAS No. [56310-80-6] | 1、2、5、10 |
| 434 | 1,7-Dimercapto-m -carborane | CAS No. [23810-64-2] | 1、2、5、10 |
| 513 | 9-Mercapto-m -carborane | CAS No. [64493-44-3] | 1、2、5、10 |
| 201 | p -Carborane | CAS No. [20644-12-6] | 1、5、10、25、50 |
| 267 | p -Carborane-1,12-dicarboxylic acid | CAS No. [23087-99-2] | 1、5、10 |
| 528 | 1-Hydroxy-p -carborane | CAS No. [54360-43-9] | 1、5、10 |
| 533 | 1,12-Dihydroxy-p -carbora | CAS No. [55629-27-1] | 1、5、10 |
| 497 | 1-Mercapto-p -carborane | CAS No. [69985-41-7] | 1、2、5、10 |
| 498 | 1,12-Dimercapto-p -carborane | CAS No. [24228-77-1] | 1、2、5、10 |
| 341 | 4,5-Dicarba-arachno -nonaborane(13) new | CAS No. [113678-30-1] | 5、10、25 |
| 339 | 4,6-Dicarba-arachno -nonaborane(13) new | CAS No. [17653-38-2] | 5、10、25 |
| 340 | 6,9-Dicarba-arachno -decaborane(14) new | 5、10、25 | |
| 227 | 5,6-Dicarba-nido -decaborane(12) | CAS No. [41655-26-9] | 5、10、20 |
| 539 | Ten-vertex-o -carborane | CAS No. [41655-27-0] | 2、5 |
| 354 | Ten-vertex-m -carborane | CAS No. [23704-81-6] | 2、5 |
| 255 | Ten-vertex-p -carborane | CAS No. [23653-12-6] | 2、5 |
| 206 | o -Carborane 10B | CAS No. [760207-79-2] | 1、5、10 |
| 207 | 1-Methyl-o -carborane 10B | CAS No. [1177403-84-7] | 1、5、10 |
| 205 | m -Carborane 10B | 1、5、10 | |
| 595 | o -Carborane 11B | CAS No. [1291083-31-2] | 1、5、10 |
| 407 | m -Carborane 11B | CAS No. [1291083-36-7] | 1、5、10 |
| 271 | COSAN | CAS No.[60146-18-1] | 1、5、10、25、50、100、250 |
| 218 | Chloro-protected cesium bis(1,2-dicarbollide)-cobaltate | CAS No.[84913-29-1] | 1、5、10、25、50、100、250 |
| 393 | Bromo-protected cesium bis(1,2-dicarbollide)-cobaltate | CAS No.[84933-24-4] | 1、5、10、50 |
| 292 | COSAN dioxanate | CAS No.[188478-29-7] | 1、2、5、10、50 |
| 476 | NISAN | CAS No.[36548-55-7] | 1、5、10、25、50 |
| 483 | FESAN | CAS No.[12304-97-1] | 1、5、10、25、50 |
| 520 | Lithium COSAN | CAS No.[167568-99-2] | 1、5 |
| 517 | Sodium COSAN | CAS No.[99492-72-5] | 1、5 |
| 392 | Sodium borohydride | CAS [16940-66-2] | 50、100、250、500、1000 |
| 429 | Rubidium borohydride | CAS [20346-99-0] | 1、2、5、10 |
| 225 | Cesium borohydride | CAS [19193-36-3] | 1、2、5、10 |
| 596 | Calcium borohydride | CAS [17068-95-0] | 1、5、10、25 |
| 636 | Magnesium borohydride | CAS [16903-37-0] | 1、5、10、25 |
| 263 | Lithium borodeuteride | CAS [15246-28-3] | 1、2、5、10 |
| 361 | Lithium borohydride 10B | 1、2、5、10 | |
| 362 | Lithium borodeuteride 10B | 1、2、5、10 | |
| 323 | Lithium borohydride 11B | 1、2、5、10 | |
| 239 | Lithium borodeuteride 11B | CAS [1242073-72-8] | 1、2、5、10 |
| 363 | Lithium borohydride 7Li | 1、2、5、10 | |
| 367 | Lithium borodeuteride 7Li | 1、2、5、10 | |
| 370 | Lithium borohydride 7Li, 10B | CAS [139980-21-5] | 1、2、5、10 |
| 371 | Lithium borodeuteride 7Li, 10B | CAS [163779-14-4] | 1、2、5、10 |
| 442 | Lithium borohydride 7Li, 11B | CAS [139980-20-4] | 2、5 |
| 499 | Lithium borodeuteride 7Li,11B | CAS [163779-13-3] | 1、2、5、10 |
| 326 | Sodium borodeuteride | CAS [15681-89-7] | 5、10 |
| 202 | Sodium borohyride 10B | CAS [72901-47-4] | 1、2、5、10 |
| 373 | Sodium borodeuteride 10B | CAS [163779-18-8] | 1、2、5、10 |
| 396 | Sodium borohyride 11B | CAS [72901-46-3] | 1、2、5、10 |
| 397 | Sodium borodeuteride 11B | CAS [163779-17-7] | 1、2、5、10 |
| 379 | Potassium borodeuteride | CAS [17440-13-0] | 5、10 |
| 455 | Potassium borohyride 10B | 1、2、5、10 | |
| 417 | Potassium borodeuteride 10B | 1、2、5、10 | |
| 447 | Potassium borohyride 11B | CAS [1417734-35-0] | 1、2、5、10 |
| 413 | Potassium borodeuteride 11B | 1、2、5、10 | |
| 508 | Calcium borodeuteride | CAS [122042-59-5] | 1、2、5、10 |
| 352 | Calcium borohydride 10B | 1、2、5、10 | |
| 355 | Calcium borohydride 11B | 1、2、5、10 | |
| 220 | Calcium borodeuteride 11B | CAS [1309461-44-6] | 1、2、5、10 |
| 656 | Magnesium borohydride 11B | 1、2、5、10 | |
| 452 | Cesium borohydride 11B | CAS [1417734-38-3] | 1、2、5、10 |
| 504 | Cesium borodeuteride 11B | 1、2、5、10 | |
| 462 | Rubidium borohydride 11B | CAS [1417734-37-2] | 1、2、5、10 |
| 505 | Rubidium borodeuteride 11B | CAS [1445366-23-3] | 1、2、5、10 |
| 300 | Dimethylamine borane complex, DMAB | CAS [74-94-2] | 10、25、100、250、1000 |
| 415 | Ammonia borane complex | CAS [13774-81-7] | 10、20、50、100 |
| 415,1 | Ammonia borane complex +90% (purity >90%) | CAS [13774-81-7] | 10、20、50、100、200、500、1000 |
| 294 | Triethylamine borane complex | CAS [1722-26-5] | 10、50、100、500 |
| 221 | Dimethylsulfide borane complex, 10M solution in Me2S (d=0.8g/ml 26°C) | CAS [13292-87-0] | 100、800 |
| 375 | Ammonia borane complex 10B | CAS [77074-21-6] | 1、5、10 |
| 468 | Ammonia borane complex 11B | CAS [77069-36-4] | 1、5、10 |
| 563 | Deuteroammonia deuteroborane complex 11B | CAS [933675-78-6] | 1、2、5 |
| 577 | Deuteroammonia deuteroborane complex | CAS [20214-17-9] | 1、2、5 |
| 435 | Triethylamine deuteroborane complex | CAS [4680-65-3] | 10、25、50、100 |
| 311 | Triethylamine borane complex 10B | CAS [115959-96-1] | 10、25、50、100 |
| 449 | Triethylamine deuteroborane complex 10B | 10、25、50、100 | |
| 430 | Triethylamine borane complex 11B | 10、25、50、100 | |
| 411 | Triethylamine deuteroborane complex 11B | 10、25、50、100 | |
| 477 | Dimethylsulfide deuteroborane complex (purity > 95%) | CAS [117981-99-4] | 10、25、50、100 |
| 254 | Dimethylsulfide borane complex 10B(purity > 95%) | 10、25、50、100 | |
| 471 | Dimethylsulfide deuteroborane complex 10B(purity > 95%) | 10、25、50、100 | |
| 594 | Dimethylsulfide borane complex 11B(purity > 95%) | 10、25、50、100 | |
| 473 | Dimethylsulfide deuteroborane complex 11B(purity > 95%) | CAS [2230877-77-5] | 10、25、50、100 |
| 219 | 4-Borono-L-phenylalanine, L-BPA | CAS [76410-58-7] | 1、5、10、50 |
| 541 | Trimethylborate | CAS [121-43-7] | 5、10、50、100、400、800 |
| 268 | 4-Borono-L-phenylalanine 10B, BPA (also provide BPA produced by GMP.) | CAS [80994-59-8] | 1、10、50 |
| 436 | Trimethylborate 10B | CAS [4832-27-3] | 5、10、50、100、400、800 |
| 262 | Tri-n-butylborate 10B | CAS [207742-80-1] | 10、50、100、400、800 |
| 344 | Triphenylborate 10B | 10、50、100、400 | |
| 409 | Trimethylborate 11B | CAS [3349-42-6] | 3、10、25、50 |
| 423 | Tri-n-butylborate 11B | CAS [207742-78-7] | 10、25、50、100 |
| 431 | Triphenylborate 11B | 10、25、50、100 | |
| 210 | Sodium mercaptododecaborate 10B, BSH | CAS [12448-24-7] | 1、5、10、50 |
| 268 | 4-Borono-L-phenylalanine 10B, BPA ( also provide BPA produced by GMP.) | CAS [80994-59-8] | 1、10、50 |
| 556 | Sodium decahydrodecaborate 10B, GB-10 | CAS [666747-96-2] | 1、5、10、25 |
| 230 | TODGA | CAS [342794-43-8] | 5、10、20、50、100 |
| 296 | DIHOCA dihexyloctanoyl amide | CAS [75397-93-2] | 5、10、20、50、100 |
| 611 | TEHDGA | CAS [669087-46-1] | 5、10、20、50、100 |
| 348 | 7Li-Lithium bromide | CAS [34007-72-2] | 5、10、20、50、100 |
| 553 | 7Li-Lithium iodide | CAS [29911-74-8] | 5、10、20 |
| 308 | 7Li-Lithium chloride | CAS [20233-17-4] | 5、10、20 |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技授权代理Katchem全系列硼化学产品"> 艾美捷科技授权代理Katchem全系列硼化学产品
艾美捷科技代理BioLab Assays 品牌。
BioLab Assays Ltd.开发、制造和销售创新和原创的即用ELISA(酶联免疫吸附测定)试剂盒。其产品组合包括固相96孔ELISA,设计用于定量测量细胞因子、急性反应物蛋白或趋化因子,并针对血清、血浆、尿液、唾液或脑脊液样品进行了优化。BioLab Assays公司产品涵盖以下领域:肥胖,IR,代谢综合征,糖尿病,肾脏疾病,肺部疾病,动物护理和研究,骨代谢,炎症和感染。
<BioLab Assays公司提供的产品和服务主要包括:
(1)即用型ELISA试剂盒:这是公司的核心产品,用于定量测量各种生物标志物,如细胞因子、急性反应物蛋白、趋化因子等。
(2)定制免疫检测开发:公司还提供定制免疫检测开发服务,以满足客户的特定需求。
(3)合同制造服务:除了自主开发和销售产品外,BioLab Assays公司还提供合同制造服务,为其他公司提供高质量的免疫检测产品。
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:18771997407
邮箱:sales@amyjet.com
0.2005